Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: December 2022 (Report dated December 19, 2022)
Context: The filing serves to distribute a press release regarding interim study results for the Company's ProSense cryoablation system in the treatment of kidney tumors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical study results and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus the prior comparable period are reported in this document. The primary update is the announcement of interim clinical data showing an 89.5% recurrence-free rate for kidney tumors treated with the ProSense system.
Guidance, Outlook, and Risks
- Management Commentary: The press release incorporated by reference highlights that the ProSense system was found to be safe and effective in treating kidney tumors based on interim study results.
- Forward-Looking Statements: The filing explicitly incorporates the "Forward Looking Statements" section from the press release into the Company's Registration Statements on Form F-3 and Form S-8.
- Risks and Contingencies: Specific risks are not detailed in the body of this Form 6-K but are referenced via the incorporation of the press release's forward-looking statements.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed clinical methodology and patient cohort sizes.
- Review the "Forward Looking Statements" section within the press release for specific risks associated with the study results.
- Confirm the status of the Company's Registration Statements (Nos. 333-258660, 333-267272, 333-262620, and 333-264578) to understand how this data impacts future capital raising.
- Check subsequent filings for any updates on the final study results or regulatory implications.